Standard: this guide onlyAll-Access Lifetime: all 45 guides + downloadsEducational content only
Cartalax Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Cartalax at a glance
What it is
Synthetic tetrapeptide bioregulator (commonly cited as Ala-Glu-Asp-Leu / AEDL) from the Khavinson short-peptide family
Researched for
Cartilage matrix and connective-tissue gene expression in preclinical and Russian observational contexts
Commonly reported range
1-2 mg/day subcutaneous, or 10-20 mg/day oral (community-reported examples)
Route reported
Subcutaneous injection or oral, as reported in community protocols
Reported frequency
Once daily during a course
Reported cycle
10-20 consecutive days, repeated 2-3 times per year
Plasma half-life
Short, estimated on the order of ~30 minutes for free peptide
Regulatory status
Not FDA-approved; research-use only; not a WADA-listed prohibited substance as a named agent
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
Cartalax is one of the short synthetic peptides developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, and is most commonly cited with the sequence Ala-Glu-Asp-Leu (AEDL). It belongs to the same "cytomedin"-derived bioregulator class as Epithalon (AEDG) and Cortagen (AEDP). The proposed mechanism, shared across this peptide family, is that these very short peptides enter cells, reach the nucleus, and interact with specific DNA/chromatin sequences to modulate tissue-specific gene expression. For Cartalax, research discussion focuses on chondrocyte and connective-tissue gene networks, including promoters associated with extracellular-matrix proteins such as type II collagen and aggrecan. This gene-regulation model is largely derived from in vitro and animal work rather than confirmed human molecular studies.
Researched effects
Reported research and community observations focus on cartilage and connective-tissue support, including matrix protein synthesis and chondrocyte activity in aging-tissue models. Some sources also describe general "bioregulator" observations consistent with the broader Khavinson peptide family. These are research findings and community-reported observations, not guaranteed outcomes, and robust human efficacy data are lacking.
Evidence & regulatory status
Evidence: supporting data comes mainly from Russian preclinical studies, cell-culture work, and observational reports on Khavinson-family peptides; rigorous Western peer-reviewed clinical trials specific to Cartalax are essentially absent.
Regulatory: Cartalax is not approved by the FDA (or EMA) for any medical use and is not an established prescription drug; it is handled as a research chemical.
Research-use: material sold as Cartalax is intended for laboratory and research use only, is not a dietary supplement or medicine, and is not intended to diagnose, treat, cure, or prevent any disease.
Dosage — reported ranges (overview)
The figures below are examples of what is reported in community protocols and secondary sources, not a recommendation or a personal dose. Injectable community examples commonly cite roughly 1-2 mg per day subcutaneously, while oral examples cite roughly 10-20 mg per day, typically run in short courses of 10-20 days and repeated a few times per year. Some research references also mention much smaller microgram-level amounts. Because human data are limited, reported ranges vary widely between sources.
The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.
Reconstitution — bac-water math
Reconstitution is concentration math only, not a personal dose. Lyophilized peptide is dissolved by adding bacteriostatic water; the concentration is the total peptide divided by the water volume. On a U-100 insulin syringe, 100 units = 1 mL, so units = (desired mg ÷ mg-per-mL) × 100. For a representative 20 mg Cartalax vial reconstituted with 2 mL of bacteriostatic water, the concentration is 20 ÷ 2 = 10 mg/mL; a 1 mg example amount is then 1 ÷ 10 = 0.1 mL, which is 10 units on a U-100 syringe.
Bac water added
Concentration
1 mg example
2 mg example
1 mL
20 mg/mL
5 units (0.05 mL)
10 units (0.10 mL)
2 mL
10 mg/mL
10 units (0.10 mL)
20 units (0.20 mL)
3 mL
6.67 mg/mL
15 units (0.15 mL)
30 units (0.30 mL)
This is concentration math, not a dose recommendation.
Pre-fills example values. Every field remains editable.
The amount printed on the vial or listed on a product page.
mL
Liquid volume used for the concentration calculation.
The mass amount to convert into liquid volume for this math example.
4. Insulin syringe size
Your result
Syringe-unit reading
10 units
= 0.1 mL · 250 mcg target amount
Concentration
2.5mg/mL
Per insulin unit
25mcg
Portions per vial
20
Volume
0.1mL
This calculator is an educational tool for laboratory and research math only. The peptides referenced are research compounds not intended for human or veterinary use, and example values are not medical advice or personal-use instructions. Follow applicable research protocols and regulations.
How the calculator works
Concentration
peptide ÷ liquid
Total peptide divided by liquid volume gives the concentration per mL.
Volume
target ÷ concentration
The target mass divided by concentration gives the liquid volume.
Syringe units
volume × 100
For insulin units, 100 units equals 1 mL, so mL is multiplied by 100.
Worked example: A 5 mg vial plus 2 mL liquid creates a 2.5 mg/mL concentration. A 250 mcg target amount equals 0.1 mL, or 10 insulin units. The vial contains 20 such portions.
Frequently asked questions
How much bacteriostatic water should I enter?+
There is no single calculator-default amount. The liquid volume controls concentration: more liquid creates a less concentrated solution and a larger volume reading for the same target amount; less liquid creates a more concentrated solution and a smaller volume reading.
How do insulin syringe units relate to mL?+
For this math tool, 100 insulin units equals 1 mL, and 1 unit equals 0.01 mL. The 0.3 mL, 0.5 mL, and 1.0 mL options change capacity, not the unit-to-mL relationship.
What is the difference between mg, mcg, and units?+
Milligrams and micrograms measure peptide mass: 1 mg = 1,000 mcg. Syringe units measure liquid volume. Reconstitution math connects mass and volume by using concentration.
Does changing the liquid volume change the total peptide in the vial?+
No. The total peptide amount entered for the vial remains fixed. Changing the liquid volume only changes concentration and the resulting volume shown by the calculator.
Injection / administration basics
In community protocols, small-volume subcutaneous injection is the route most often described, using a U-100 insulin syringe into subcutaneous tissue such as the abdomen, with standard aseptic handling (single-use needles, alcohol swab, no sharing). Oral use is also described in some Khavinson-peptide contexts. None of this is medical guidance; anyone considering use should consult a licensed clinician.
Half-life & frequency rationale
Like other short Khavinson peptides, the free peptide is thought to have a very short plasma half-life, on the order of about 30 minutes, which is why courses are dosed daily over consecutive days rather than relying on sustained blood levels; proposed effects are attributed to downstream gene-expression changes rather than prolonged circulation. Precise human pharmacokinetic data are limited.
Side effects, safety & contraindications
Short Khavinson peptides are generally described in the available literature as well tolerated, with no serious adverse events documented in the limited published and observational reports; minor injection-site reactions (redness, soreness) are the most commonly mentioned. Human safety data specific to Cartalax are very limited, long-term safety is not established, and the absence of reported harm is not the same as proven safety.
Stacking — overview
Cartalax is community-reported to be combined with other tissue-repair and bioregulator peptides in joint- and connective-tissue-focused protocols. These are examples of pairings discussed in the community, not recommendations, and evidence for any specific combination is minimal.
Joint & Tissue Repair
Cartalax + BPC-157 + TB-500
Connective Matrix / Collagen
Cartalax + GHK-Cu
Bioregulator Longevity
Cartalax + Epithalon
Storage & handling
Lyophilized (powder): store sealed and protected from light; refrigerated (2-8 C) is common, and freezing supports longer-term storage.
Reconstituted (in bacteriostatic water): keep refrigerated at 2-8 C, protect from light, and use within a few weeks.
References
Information is compiled from vendor monographs, peptide-education sites, and secondary summaries of Khavinson short-peptide bioregulator research; primary Western clinical trials specific to Cartalax are not available.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
What is Cartalax?
Cartalax is a synthetic short-peptide bioregulator from the Khavinson family, most often cited with the sequence Ala-Glu-Asp-Leu (AEDL) and discussed in research in connection with cartilage and connective tissue. It is a research compound, not an approved medicine.
What sequence is Cartalax, AEDL or AEDP?
Sources vary, but Cartalax is most commonly listed as Ala-Glu-Asp-Leu (AEDL). The related sequence Ala-Glu-Asp-Pro (AEDP) is usually attributed to Cortagen, a different Khavinson peptide, so labels should be checked carefully.
Is Cartalax FDA-approved or banned in sport?
Cartalax is not FDA-approved for any use and is sold for research only. It is not listed by name on the WADA prohibited list, but athletes should not assume any non-approved peptide is compliant and should verify current anti-doping rules.
How is Cartalax reconstituted?
Bacteriostatic water is added to the lyophilized powder; concentration equals total mg divided by mL of water. For example, a 20 mg vial with 2 mL of water gives 10 mg/mL. This is concentration math, not a personal dose.
What dosages are reported for Cartalax?
Community and secondary sources report examples around 1-2 mg/day subcutaneously or 10-20 mg/day orally, in short 10-20 day courses. These are reported examples only, not medical advice, and human data are limited.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
